Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 2/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15933275 | 0.87 | F11 (0.40) | MAPTAAK1F11 | |
| SCHEMBL15915969 | 0.87 | AAK1 (0.35) | MAPTAAK1IDO1F11SSTR3 | |
| SCHEMBL10257124 | 0.85 | MAPT (0.35) | MAPTAAK1IDO1SSTR3NPSR1 | |
| SCHEMBL12352296 | 0.80 | MAPT (0.40) | MAPTAAK1IDO1F11CCKAR | |
| SCHEMBL16974681 | 0.78 | MAPT (0.37) | MAPTAAK1SSTR3MEN1KMT2A | |
| SCHEMBL10257068 | 0.78 | MAPT (0.37) | MAPTAAK1SSTR3MEN1KMT2A | |
| SCHEMBL28596508 | 0.78 | MAPT (0.37) | MAPTAAK1NPSR1 | |
| SCHEMBL21741526 | 0.78 | MAPT (0.38) | MAPTAAK1F11MEN1KMT2A | |
| SCHEMBL14692572 | 0.77 | ALDH1A1 (0.33) | MAPTAAK1F11MEN1KMT2A | |
| SCHEMBL14692571 | 0.77 | ALDH1A1 (0.33) | MAPTAAK1F11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-20 | — | — | US | disclosed |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F11 | MAPT 693/4885AAK1 802/4885IDO1 683/4885 |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | MAPT 693/4885AAK1 802/4885IDO1 683/4885 |
| US-20120309960-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | MAPT 326/4885AAK1 896/4885IDO1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.